<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Immunotherapy on FinanClub</title>
    <link>https://finan.club/tags/immunotherapy/</link>
    <description>Recent content in Immunotherapy on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Mon, 18 Dec 2023 00:56:00 +0000</lastBuildDate><atom:link href="https://finan.club/tags/immunotherapy/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>IBRX</title>
      <link>https://finan.club/us/ibrx/</link>
      <pubDate>Mon, 18 Dec 2023 00:56:00 +0000</pubDate>
      
      <guid>https://finan.club/us/ibrx/</guid>
      <description>score:126
Chances: ImmunityBio, Inc. is making significant progress in its clinical-stage immunotherapy development, as evidenced by its participation in the 35th Annual Piper Sandler Healthcare Conference and the acceptance for review of its Biologics License Application by the FDA. The company&amp;rsquo;s Memory Cytokine-Enriched Natural Killer cells (M-ceNK) have shown promising results in the treatment of small cell lung cancer and neuroendocrine tumors, indicating a potential breakthrough in immunotherapy.</description>
    </item>
    
  </channel>
</rss>
